Growing Market Potential Small Pharma operates within the rapidly expanding psychedelic-assisted therapy market, which is witnessing increased industry consolidation and investor interest, offering significant opportunities for partnerships, licensing, and clinical trial collaborations.

Innovative Product Pipeline The company's focus on developing short-duration, DMT-based treatments for mental health conditions positions it at the forefront of novel therapeutic solutions, creating sales opportunities with mental health clinics, healthcare providers, and research institutions seeking cutting-edge treatments.

Strategic Industry Position Following its acquisition by Cybin, Small Pharma’s integration into a larger biotech ecosystem enhances its credibility and reach, facilitating potential sales of research services, intellectual property licensing, and collaborative product development.

Research & Intellectual Property With ongoing updates to its IP portfolio and clinical advancements, Small Pharma presents opportunities for licensing, joint ventures, and research partnerships with organizations interested in expanding psychedelic therapy offerings.

Clinical Data & Validation Positive top-line clinical results for DMT-assisted therapy demonstrate promising efficacy, creating potential sales avenues for medical device providers, health insurers, and mental health service providers eager to adopt validated innovative therapies.